Cardiovascular Medicine: Diagnostics, Drugs and Devices

Table of Contents

• Cardiovascular Medicine: Diagnostics, Drugs and Devices
• Chapter 1 - SUMMARY
• THE CARDIOVASCULAR DIAGNOSTIC, DRUG, AND DEVICE MARKETS
• Summary Table: WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, THROUGH 2012 ($ BILLIONS)
• Summary Figure: WORLDWIDE REVENUE OF CARDIOVASCULAR DIAGNOSTICS, DRUGS, AND DEVICES, 2005-2012 ($ BILLIONS)
• Chapter 2 - OVERVIEW
  • WHAT IS CARDIOVASCULAR (CV) DISEASE?
  • CAUSES OF CARDIOVASCULAR DISEASE
  • CAUSES OF CARDIOVASCULAR DISEASE (CONTINUED)
  • CARDIOVASCULAR DIAGNOSTICS
  • CARDIOVASCULAR MEDICINE
  • CARDIOVASCULAR DEVICES
• Chapter 3 - CARDIOVASCULAR DISEASES
  • DISEASES OF THE HEART (CARDIO) AND DISEASES OF THE BLOOD VESSELS (VASCULAR)
  • DISEASES OF THE HEART
    • Coronary Artery Disease (CAD)
    • Coronary Heart Disease (CHD)
    • Cardiomyopathy
    • Valvular Heart Disease
    • Pericardial Disease
    • Congenital Heart Disease
    • Heart Failure
• DISEASE OF BLOOD VESSELS
  • Arteriosclerosis and Atherosclerosis
  • High Blood Pressure
  • Stroke
  • Aneurysm
  • Peripheral Arterial Disease and Claudication (PAD)
  • Vasculitis
  • Venous Incompetence
  • Venous Thrombosis
  • Varicose Veins
  • Lymphedema
• EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE
  • Global Distribution Pattern in 2004
  • Age
  • Gender
  • Role of Risk Factors
  • Risk Factors
  • Psychological and Social Factors
  • Prevention of Cardiovascular Disease
• Chapter 4 - PREVALANCE OF CARDIOVASCULAR DISEASES
  • MAJOR CAUSE OF DEATH
    • THE EPIDEMIOLOGICAL TRANSITION
    • PREVALENCE OF HEART DISEASE IN VARIOUS CATEGORIES
      • Age
      • Gender
      • Race/ Ethnicity
      • Education
• Table 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY VARIOUS CATEGORIES, 2005
• Figure 1 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY AGE GROUP, 2005 (%)
• Figure 2 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY GENDER, 2005 (%)
• Figure 3 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY RACE/ETHINICITY, 2005 (%)
• Figure 4 PREVALENCE OF STROKE, MYOCARDIAL INFARCTION, AND ANGINA PECTORIS BY EDUCATION 2005 (%)
• PREVALENCE OF CARDIOVASCULAR DISEASES IN THE U.S.
• Table 2 PREVALENCE OF CARDIOVASCULAR DISEASES IN U.S., 2005 (MILLION PEOPLE)
• Figure 5 PREVALENCE OF CARDIOVASCULAR DISEASES IN THE U.S., 2005 (MILLION PEOPLE)
  • COST OF CARDIOVASCULAR DISEASES IN THE U.S.
• Table 3 COST OF CARDIOVASCULAR DISEASES IN U.S. THROUGH 2012 ($ BILLIONS)
• Figure 6 COST OF CARDIOVASCULAR DISEASES IN THE U.S., 2005-2012 ($ BILLIONS)
  • PREVALENCE AND COST OF CARDIOVASCULAR DISEASES IN EUROPE
  • MORTALITY DUE TO CARDIOVASCULAR DISEASES
  • U.S.
• Table 4 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)
• Table 4 (CONTINUED)
• Figure 7 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S. 2005 (%)
  • Europe
• Table 5 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN EUROPE, 2005 (%)
• Figure 8 MORTALITY DUE TO CARDIOVASCULAR DISEASES IN THE U.S., 2005 (%)
• Chapter 5 - REGULATORY ISSUES
  • CARDIOVASCULAR DRUGS APPROVED BY FDA
• Table 6 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002-2007*
• Figure 9 CARDIOVASCULAR DRUGS APPROVED BY FDA, 2002-2007*
  • CARDIOVASCULAR DEVICES APPROVED BY THE FDA
• Table 7 CARDIOVASCULAR DEVICES APPROVED BY THE FDA, 2002-2007*
• Table 7 (CONTINUED)
• Table 7 (CONTINUED)
• Figure 10 CARDIOVASCULAR DEVICES APPROVED BY THE FDA 2002-2007*
  • CARDIOVASCULAR DRUGS RECALLED BY FDA
• Table 8 CARDIOVASCULAR DRUGS RECALLED BY THE FDA, 2002-2007*
  • CARDIOVASCULAR DEVICES RECALLED BY FDA
• Table 9 CARDIOVASCULAR DEVICES RECALLED BY THE FDA, 2002-2007*
• Table 9 (CONTINUED)
• Figure 11 CARDIOVASCULAR DEVICES RECALLED BY FDA, 2002-2007*
• Figure 11 (CONTINUED)
  • NEW DRUG APPLICATIONS
    • NEW DRUG APPLICATIONS (CONTINUED)
    • NEW DRUG APPLICATIONS (CONTINUED)
• Chapter 6 - CARDIOVASCULAR DIAGNOSTICS
  • DIAGNOSTICS DEFINITION
  • IN VITRO DIAGNOSTIC
  • BIOMARKERS
    • Aspartate Aminotransferase (AST/GOT)
    • Lactate Dehydrogenase and its Isoenzyme LD
    • Creatine Kinase (CK) and its Isoenzyme MB
    • Myoglobin
    • Cardiac Troponins
      • Reasons behind the Replacement of CKMB with Troponins
      • Myoglobin/Carbonic Anhydrase III Ratio
      • Glycogen Phosphorylase Isoenzyme BB
      • Heart Type Fatty Acid Binding Protein
  • COMPARISON BETWEEN CTNT AND CTNL
    • Natriuretic Peptides as Cardiac Biomarkers
• Table 10 NT-PROBNP IN ACUTE SITUATIONS
• Table 11 NT-PROBNP IN PRIMARY CARE SETTING
  • POINT-OF-CARE TESTING
    • NEED FOR THE POCT
• Table 12 ADVANTAGES OF POINT OF CARE TESTING
• Table 13 DISADVANTAGES OF POINT OF CARE TESTING
  • Past, Present, and Future of Point-of-Care Testing
    • Past
    • Present
    • Future
  • DETERMINING WHETHER TO USE POC CARDIAC TESTING IN THE ED
    • Considerations of Turnaround Times
    • The Importance of Quantitative Results
    • Concerns about Standardization
  • VENUES FOR POC TESTING
• Table 14 VENUES FOR POC TESTING
  • IN VIVO DIAGNOSTICS
    • ECHOCARDIOGRAPHY
      • Need of the Echocardiography
• Table 15 TYPES OF ECHOCARDIOGRAMS
  • ULTRASOUND
• Table 16 TYPES OF DOPPLER ULTRASOUND
  • Advantages of Ultrasound
• MRI
  • Need of MRI Scan
  • POSITRON EMISSION TOMOGRAPHY
  • COMPUTED TOMOGRAPHY
    • Electron-Beam Computed Tomography (EBCT or Ultrafast CT)
      • Electron-Beam Computed (Continued)
• Chapter 7 - CARDIOVASCULAR THERAPY
  • CARDIOVASCULAR DRUGS
  • ANTI-ANGINAL AGENTS
• Table 17 COMMONLY USED ANTI-ANGINAL AGENTS
  • ANTI-ARRHYTHMIC AGENTS
• Table 18 COMMONLY USED ANTI-ARRHYTHMIC AGENTS
  • ANTI-HYPERTENSIVE DRUGS
• Table 19 COMMONLY USED ANTI-HYPERTENSIVE AGENTS
  • ANTI-THROMBOTIC AGENTS
  • BLOOD LIPID LOWERING AGENTS
• Table 20 COMMONLY USED BLOOD LIPID LOWERING AGENTS
  • DRUGS USED TO TREAT CONGESTIVE HEART FAILURE
• Table 21 COMMONLY USED DRUGS TO TREAT CONGESTIVE HEART FAILURE
  • CARDIOVASCULAR DEVICES
  • PACEMAKERS
• Table 22 PACEMAKERS
  • Defibrillators
  • Manual External Defibrillators
    • Manual Internal Defibrillator
    • Automated External Defibrillator
    • Semi-automated External Defibrillator
    • Implantable Cardioverter Defibrillator
  • Drug-Eluting Stents (DES)
  • Catheters
  • Valves
    • Mechanical Heart Valve
    • Biological Heart Valve
  • Ventricular Assist Device
  • Guidewires
  • Artificial Heart
• CARDIAC RESYNCHRONIZATION THERAPY
  • Cardiac Resynchronization Therapy
  • Cardiac Resynchronization Therapy Devices
  • Difference between Biventricular Pacemaker and Standard Pacemaker
  • Use of CRT
  • Benefits of CRT
  • Potential Risks with Biventricular Pacemakers
• Chapter 8 - INDUSTRY STRUCTURE
  • CARDIOVASCULAR DIAGNOSTICS
  • CARDIAC BIOMARKERS
• Table 23 PRESENT CARDIAC MARKER TESTING
  • Market Shares for Companies Providing Biomarker Tests
• Table 24 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)
• Figure 12 MARKET SHARE OF COMPANIES PROVIDING BIOMARKER TESTS, 2006 (%)
  • Effect of POCT on the Growth of Cardiac Biomarker Testing in Laboratory
  • POINT OF TESTING FOR CARDIAC BIOMARKERS
• Table 25 PRESENT POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS
  • Market Shares for Companies Providing Biomarker Tests
• Table 26 MARKET SHARE OF COMPANIES PROVIDING POINT-OF-CARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)
• Figure 13 MARKET SHARE OF COMPANIES PROVIDING POINT-OF CARE TESTING FOR CARDIAC BIOMARKERS, 2006 (%)
  • Factors Influencing the Growth of Point-of-Care Testing
  • Challenges for the Manufacturers
  • IN-VIVO DIAGNOSTICS
• Table 27 PRESENT IMAGING SYSTEMS FOR IN-VIVO DIAGNOSIS
• Market Shares for Companies Providing In-Vivo Diagnostics
• Table 28 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)
• Figure 14 MARKET SHARE OF COMPANIES PROVIDING IN-VIVO DIAGNOSTICS, 2006 (%)
  • Factors Affecting the Growth of Cardiac Imaging or In vivo Diagnostics
  • CARDIOVASCULAR DRUGS
  • ANTI-ANGINAL AGENTS
• Table 29 GLOBAL MARKET LEADERS OF ANTI-ANGINAL AGENTS
  • Market Shares for Anti-anginal Agents
• Table 30 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)
• Figure 15 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ANGINAL AGENTS, 2006 (%)
  • ANTI-ARRYHTHMIC AGENTS
• Table 31 GLOBAL MARKET LEADERS OF ANTI-ARRHYTHMIC AGENTS
  • Market Shares for Anti-arrhythmic Agents
• Table 32 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)
• Figure 16 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-ARRHYTHMIC AGENTS, 2006 (%)
  • ANTI-HYPERTENSIVE AGENTS
• Table 33 GLOBAL MARKET LEADERS OF ANTI-HYPERTENSIVE AGENTS
  • Market Shares for Anti-hypertensive Agents
• Table 34 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)
• Figure 17 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-HYPERTENSIVE AGENTS, 2006 (%)
• ANTI-THROMBOTIC AGENTS
• Table 35 GLOBAL MARKET LEADERS OF ANTI-THROMBOTIC AGENTS
• Market Shares for Anti-thrombotic Agents
• Table 36 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)
• Figure 18 MARKET SHARE OF COMPANIES MANUFACTURING ANTI-THROMBOTIC AGENTS, 2006 (%)
  • BLOOD LIPID LOWERING AGENTS
• Table 37 GLOBAL MARKET LEADERS OF BLOOD LIPID LOWERING AGENTS
  • Market Shares for Blood Lipid Lowering Agents
• Table 38 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)
• Figure 19 MARKET SHARE OF COMPANIES MANUFACTURING BLOOD LIPID LOWERING AGENTS, 2006 (%)
  • DRUGS TREATING CONGESTIVE HEART FAILURE
• Table 39 GLOBAL MARKET LEADERS OF DRUGS TREATING CONGESTIVE HEART FAILURE
  • Market Shares for Drugs Treating Congestive Heart Failure
• Table 40 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)
• Table 40 (CONTINUED)
• Figure 20 MARKET SHARE OF COMPANIES MANUFACTURING DRUGS TREATING CONGESTIVE HEART FAILURE, 2006 (%)
  • FACTORS AFFECTING THE SALES OF CARDIOVASCULAR DRUGS
    • Price Control/ Price pressure
    • Expiration of Patents
  • MAJOR FACTORS FOR FUTURE GROWTH
    • Life Expectancy
    • Access of Senior Citizens to Prescription Drugs
    • Patent Protection
    • Drugs Portfolio Management
    • Significant Potential of Developing Countries
• CARDIOVASCULAR DEVICES
  • PACEMAKERS
• Table 41 GLOBAL MARKET LEADERS OF MANUFACTURERS OF PACEMAKERS
  • Market Shares of Companies Manufacturing Pacemakers
• Table 42 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)
• Figure 21 MARKET SHARE OF COMPANIES MANUFACTURING PACEMAKERS, 2006 (%)
  • CARDIOVERTER DEFIBRILLATORS
• Table 43 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CONVENTIONAL CARDIOVERTER DEFIBRILLATORS
• Table 44 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CRT-DEFIBRILLATORS
  • Market Shares of Companies Manufacturing Conventional Cardioverter Defibrillators
• Table 45 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)
• Figure 22 MARKET SHARE OF COMPANIES MANUFACTURING CONVENTIONAL CARDIOVERTER DEFIBRILLATORS, 2006 (%)
  • Market Shares of Companies Manufacturing CRT-Defibrillators
• Table 46 MARKET SHARE OF COMPANIES MANUFACTURING CRT-DEFIBRILLATORS, 2006 (%)
• Figure 23 MARKET SHARE OF COMPANIES MANUFACTURING CRT-DEFIBRILLATORS, 2006 (%)
  • DRUG ELUTING STENTS
• Table 47 GLOBAL MARKET LEADERS OF MANUFACTURERS OF DRUG ELUTING STENTS
• Market Shares of Companies Manufacturing Drug Eluting Stents
• Table 48 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)
• Figure 24 MARKET SHARE OF COMPANIES MANUFACTURING DRUG ELUTING STENTS, 2006 (%)
  • CATHETERS
• Table 49 GLOBAL MARKET LEADERS OF MANUFACTURERS OF CATHETERS
• Table 49 (CONTINUED)
  • Market Shares of Companies Manufacturing Catheters
• Table 50 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)
• Figure 25 MARKET SHARE OF COMPANIES MANUFACTURING CATHETERS, 2006 (%)
  • HEART VALVES
• Table 51 GLOBAL MARKET LEADERS OF MANUFACTURERS OF HEART VALVES
  • Market Shares of Companies Manufacturing Heart Valves
• Table 52 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)
• Figure 26 MARKET SHARE OF COMPANIES MANUFACTURING HEART VALVES, 2006 (%)
  • VENTRICULAR ASSIST DEVICE
• Table 53 GLOBAL MARKET LEADERS OF MANUFACTURERS OF VENTRICULAR ASSIST DEVICES
  • Market Shares of Companies Manufacturing Ventricular Assist Devices
• Table 54 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)
• Figure 27 MARKET SHARE OF COMPANIES MANUFACTURING VENTRICULAR ASSIST DEVICES, 2006 (%)
  • GUIDE WIRES
• Table 55 GLOBAL MARKET LEADERS OF MANUFACTURERS OF GUIDE WIRES
  • Market Shares of Companies Manufacturing Guidewires
• Table 56 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)
• Figure 28 MARKET SHARE OF COMPANIES MANUFACTURING GUIDEWIRES, 2006 (%)
  • FACTORS AFFECTING THE SALES OF CARDIOVASCULAR DEVICES
    • Aging Baby-Boomers
    • Regulation
    • Competitive Landscape of Technology
    • Shortening of Patent Lives
    • Business Taxes
• Chapter 9 - MARKET ANALYSIS OF CARDIOVASCULAR DIAGNOSTICS
  • CARDIAC BIOMARKERS
• Table 57 GLOBAL SALES OF CARDIAC BIOMARKERS, THROUGH 2012 ($ MILLIONS)
• Figure 29 GLOBAL SALES OF CARDIAC BIOMARKERS, 2005-2012 ($ MILLIONS)
  • CARDIAC MARKER TESTING BY TYPE
• Table 58 ESTIMATED WORLDWIDE MARKET FOR CARDIAC MARKER TESTING BY TYPE, THROUGH 2012 ($ MILLIONS)
• Figure 30 GLOBAL SALES OF CARDIAC BIOMARKERS, BY TYPE, 2005-2012 ($ MILLIONS)
  • POINT-OF-CARE TESTING
• Table 59 GLOBAL SALES OF POINT-OF-CARE TESTING, THROUGH 2012 ($ MILLIONS)
• Figure 31 GLOBAL SALES OF POINT-OF-CARE TESTING, 2005-2012 ($ MILLIONS)
  • IN VIVO DIAGNOSTICS
  • In Vivo Diagnostics (Continued)
• Table 60 GLOBAL SALES OF IN-VIVO DIAGNOSTICS, THROUGH 2012 ($ MILLIONS)
• Figure 32 GLOBAL SALES OF IN VIVO DIAGNOSTICS. 2005-2012 ($ MILLIONS)
• TOTAL MARKET SHARES OF CARDIOVASCULAR DIAGNOSTICS WORLDWIDE
• Table 61 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%)
• Figure 33 WORLDWIDE MARKET SHARE OF CARDIOVASCULAR DIAGNOSTICS, 2006 (%)
• Chapter 10 - MARKET ANALYSIS OF CARDIOVASCULAR DRUGS
  • ANTI-ANGINAL AGENTS
• Table 62 GLOBAL SALES OF ANTI-ANGINAL DRUGS, THROUGH 2012 ($ BILLIONS)
• Figure 34 GLOBAL SALES OF ANTI-ANGINAL DRUGS, 2005-2012($ BILLIONS)
  • ANTI-ARRHYTHMIC AGENTS
• Table 63 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, THROUGH 2012 ($ BILLIONS)
• Figure 35 GLOBAL SALES OF ANTI-ARRHYTHMIC DRUGS, 2005-2012 ($ BILLIONS)
  • ANTI-HYPERTENSIVE AGENTS
• Table 64 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, THROUGH 2012 ($ BILLIONS)
• Figure 36 GLOBAL SALES OF ANTI-HYPERTENSIVE DRUGS, 2005-2012 ($ BILLIONS)
  • ANTI-THROMBOTIC AGENTS
• Table 65 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, THROUGH 2012 ($ BILLIONS)
• Figure 37 GLOBAL SALES OF ANTI-THROMBOTIC DRUGS, 2005-2012 ($ BILLIONS)
  • BLOOD LIPID LOWERING AGENTS
• Table 66 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, THROUGH 2012 ($ BILLIONS)
• Figure 38 GLOBAL SALES OF BLOOD LIPID LOWERING DRUGS, 2005-2012 ($ BILLIONS)
  • DRUGS USED TO TREAT CONGESTIVE HEART FAILURE
• Table 67 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, THROUGH 2012 ($ BILLIONS)
• Figure 39 GLOBAL SALES OF DRUGS USED TO TREAT CONGESTIVE HEART FAILURE, 2005-2012 ($ BILLIONS)
  • TOTAL WORLDWIDE MARKET SHARES OF CARDIOVASCULAR DRUGS
• Table 68 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%)
• Figure 40 MARKET SHARE OF CARDIOVASCULAR DRUGS, 2006 (%)
• Chapter 11 - CARDIOVASCULAR DEVICES MARKET ANALYSIS
  • PACEMAKERS
• Table 69 GLOBAL SALES OF PACEMAKERS, THROUGH 2012 ($ MILLIONS)
• Figure 41 GLOBAL SALES OF PACEMAKERS, 2005-2012 ($ MILLIONS)
  • IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
• Table 70 GLOBAL SALES OF CONVENTIONAL IMPLANTABLE CARDIOVERTER DEVICES, THROUGH 2012 ($ MILLIONS)
• Figure 42 GLOBAL SALES OF IMPLANTABLE CARDIOVERTER DEVICES, 2005-2012 ($ MILLIONS)
• Table 71 GLOBAL SALES OF CRT-DEFIBRILLATORS, THROUGH 2012 ($ MILLIONS)
• Figure 43 GLOBAL SALES OF IMPLANTABLE CRT-DEFIBRILLATORS, 2005-2012 ($ MILLIONS)
• DRUG ELUTING STENTS (DES) AND GRAFTS
• Drug Eluting Stents (DES) and Grafts (Continued)
• Table 72 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, THROUGH 2012 ($ MILLIONS)
• Figure 44 GLOBAL SALES OF DRUG ELUTING STENTS AND GRAFTS, 2005-2012 ($ MILLIONS)
  • CATHETERS
• Table 73 GLOBAL SALES OF CATHETERS, THROUGH 2012 ($ MILLIONS)
• Figure 45 GLOBAL SALES OF CATHETERS, 2005-2012 ($ MILLIONS)
  • HEART VALVES
• Table 74 GLOBAL SALES OF HEART VALVES, THROUGH 2012 ($ MILLIONS)
• Figure 46 GLOBAL SALES OF HEART VALVES, THROUGH 2012 ($ MILLIONS)
  • VENTRICULAR ASSIST DEVICES
• Table 75 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, THROUGH 2012 ($ MILLIONS)
• Figure 47 GLOBAL SALES OF VENTRICULAR ASSIST DEVICES, 2005-2012 ($ MILLIONS)
  • GUIDEWIRES
• Table 76 GLOBAL SALES OF GUIDEWIRES, THROUGH 2012 ($ MILLIONS)
• Figure 48 GLOBAL SALES OF GUIDEWIRES, 2005-2012 ($ MILLIONS)
  • ARTIFICIAL HEART
  • TOTAL MARKET SHARES OF CARDIOVASCULAR DEVICES WORLDWIDE
• Table 77 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)
• Figure 49 MARKET SHARE OF CARDIOVASCULAR DEVICES, 2006 (%)
• Chapter 12 - NEW DEVELOPMENTS/ TECHNOLOGICAL INNOVATIONS
  • DIAGNOSTICS
    • SIEMENS MEDICAL SOLUTIONS
    • NEUROSONIX LTD
    • UNIVERSITY HOSPITAL MANNHEIM AND OSPEDALI RIUNITI DI BERGAMO
    • SORIN
    • PHILIPS
    • TOPSPIN MEDICAL
    • SONOSITE, INC.
    • DATASCOPE CORPORATION
    • RESPONSE BIOMEDICAL
    • ASTRAZENECA
    • BMS & PFIZER
    • DECODE GENETICS
    • ENCYSIVE PHARMACEUTICALS INC.
    • EPIX PHARMACEUTICALS, INC.
    • LEXICON PHARMACEUTICALS
    • MERCK & COMPANY
    • MOMENTA PHARMACEUTICALS, INC.
    • NILE THERAPEUTICS, INC.
    • PHARMACOPEIA
    • SANOFI-AVENTIS
    • TAKEDA PHARMACEUTICAL
    • UNIVERSITY OF NORTH CAROLINA
  • DEVICES
    • ABBOTT
    • ABIOMED, INC.
    • ATS MEDICAL
    • CARDIATIS
    • CRYOCATH TECHNOLOGIES, INC.
    • CRYOCOR, INC.
    • EDWARD LIFESCIENCES
    • MEDTRONIC, INC.
    • METHODIST DEBAKEY HEART CENTER
    • ST. JUDE MEDICAL, INC.
  • STEM CELLS AND HEART DISEASE
    • STEM CELLS AND HEART DISEASE (CONTINUED)
• Chapter 13 - PATENT ANALYSIS
  • TOTAL PATENTS
    • PATENTS BY YEAR
• Table 78 TOTAL NUMBER OF SIGNIFICANT PATENTS, 2005-2007
• Figure 50 NUMBER OF PATENTS, 2005-2007
• Figure 51 NUMBER OF PATENTS, SHARE BY YEAR, 2005-2007 (%)
  • PATENTS BY COUNTRY
• Table 79 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007
• Figure 52 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2007
  • DIAGNOSTICS PATENTS
  • PATENTS BY YEAR
• Table 80 PATENTS FOR DIAGNOSTICS BY YEAR, 2005-2007
• Figure 53 PATENTS FOR DIAGNOSTICS BY YEAR, 2005-2007
• PATENTS BY COUNTRY
• Table 81 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007
• Figure 54 PATENTS BY COUNTRY FOR DIAGNOSTICS, 2005-2007
  • PATENTS BY COMPANY
• Table 82 NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS
• Table 82 (CONTINUED)
• Figure 55 TOTAL NUMBER OF PATENTS BY COMPANY FOR DIAGNOSTICS, 2005-2007
  • PATENTS BY ASSIGNEE
• Table 83 NUMBER OF PATENTS BY ASSIGNEE FOR DIAGNOSTICS, 2005-2007
• Figure 56 NUMBER OF PATENTS BY ASSIGNEE FOR DIAGNOSTICS, 2005-2007
  • DRUG PATENTS
  • PATENTS BY COUNTRY
• Table 84 PATENTS BY COUNTRY FOR DRUGS, 2005-2007
• Figure 57 PATENTS BY COUNTRY FOR DRUGS, 2005-2007
  • PATENTS BY COMPANY
• Table 85 NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-2007
• Table 85 (CONTINUED)
• Figure 58 TOTAL NUMBER OF PATENTS BY COMPANY FOR DRUGS, 2005-2007
  • Patents by Assignee
• Table 86 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
• Figure 59 NUMBER OF PATENTS BY ASSIGNEE FOR DRUGS, 2005-2007
  • DEVICE PATENTS
  • PATENTS BY YEAR
• Table 87 PATENTS FOR DEVICES BY YEAR, 2005-2007
• Figure 60 PATENTS FOR DEVICES BY YEAR, 2005-2007
  • PATENTS BY COUNTRY
• Table 88 PATENTS BY COUNTRY FOR DEVICES, 2005-2007
• Figure 61 PATENTS BY COUNTRY FOR DEVICES, 2005-2007
  • PATENTS BY COMPANY
• Table 89 NUMBER OF PATENTS BY COMPANY FOR DEVICES, 2005-2007
• Table 89 (CONTINUED)
• Figure 62 TOTAL NUMBER OF PATENTS BY COMPANY FOR DEVICES, 2005-2007
  • PATENTS BY ASSIGNEE
• Table 90 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
• Figure 63 NUMBER OF PATENTS BY ASSIGNEE FOR DEVICES, 2005-2007
• Chapter 14 - COMPANY PROFILES FOR DIAGNOSTICS
  • ABBOTT LABORATORIES INC.
  • AXIS-SHIELD PLC
  • BAYER AG
  • BECKMAN COULTER INC.
  • BIOMÉRIEUX INC.
  • BIOSITE INCORPORATED
  • BIOSOUND ESAOTE INC.
  • CAMBRIDGE HEART INC.
  • CHOLESTECH
  • COVIDIEN
  • DADE BEHRING INC.
  • DELTEX MEDICAL GROUP PLC
  • EPIX PHARMACEUTICALS, INC.
  • EP MEDSYSTEMS
  • FONAR CORPORATION
  • GE HEALTHCARE
  • HYPERTENSION DIAGNOSTIC INC.
  • INVERNESS MEDICAL INNOVATIONS, INC
  • MALLINCKRODT
  • MEDISON AMERICA INC.
  • MORTARA INSTRUMENT INC.
  • OLYMPUS AMERICA INC.
  • ORTHO-CLINICAL DIAGNOSTICS, INC. (JOHNSON & JOHNSON CO.)
  • PHILIPS MEDICAL SYSTEM
  • PREMD INC.
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE HOLDING
  • SIEMENS
  • SONOSITE
  • SONOSITE (CONTINUED)
  • Chapter 15 - COMPANY PROFILES FOR DRUGS
  • ABBOTT LABORATORIES INC.
  • ASTRAZENECA PLC
  • BAYER HEALTHCARE PHARMACEUTICALS INC.
  • BIOVAIL CORPORATION
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB COMPANY
  • CV THERAPEUTICS INC.
  • HOFFMAN-LA ROCHE INC.
  • KRKA GROUP
  • LES LABORATORIES SERVIER
  • MERCK & CO. INC.
  • MERCK KGAA
  • NOVARTIS AG
  • PFIZER INC.
  • SANOFI AVENTIS
  • SCHERING PLOUGH
  • SOLVAY S.A.
  • UCB
  • WYETH
  • ZENTIVA N.V.
• Chapter 16 - COMPANY PROFILES FOR DEVICES
  • AMBU INTERNATIONAL AS
  • ANGIODYNAMICS INC.
  • ASAHI INTECC CO., LTD.
  • ATS MEDICAL INC.
  • BACCHUS VASCULAR
  • BIOHEART INC.
  • BIOSENSOR INTERNATIONAL GROUP
  • BOSTON SCIENTIFIC CORPORATION
  • CARDIMA INC.
  • CONOR MEDSYSTEMS, LLC
  • COOK GROUP
  • CORDIS CORPORATION (JOHNSON &JOHNSON CO.)
  • COREVALVE
  • C.R. BARD INC.
  • CRYOCATH
  • CRYOCOR
  • DATASCOPE CORP.
  • EDWARD LIFESCIENCES CORP.
  • GOODMAN CO. LTD.
  • HANSEN MEDICAL
  • HOSPIRA
  • JAPAN LIFELINE
  • MEDTRONIC
  • MERIT MEDICAL SYSTEM INC.
  • NMT MEDICAL INC.
  • POSSIS MEDICAL
  • SORIN GROUP
  • ST.JUDE MEDICAL
  • TERUMO
  • THORATEC
  • VASCULAR SOLUTIONS INC.
  • WORLD HEART CORP.
  • ZOLL MEDICAL INC.
• Chapter 17 - APPENDIX
  • Table 91 ACRONYMS
  • Table 91 (CONTINUED)
  • Table 91 (CONTINUED)